Lilly Completes Acquisition of AtaiBeckley
Eli Lilly completed its acquisition of AtaiBeckley, a clinical-stage biopharmaceutical company developing neuroplastogens for treatment-resistant depression, after shareholder approval.
Read the full coverage, free
We only link to sources you can read without a subscription. How we check.